Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous IL-7-expressing TILs ADP-TILIL7

A preparation of autologous tumor infiltrating lymphocytes (TILs) engineered to express the cytokine interleukin-7 (IL-7), with potential immunomodulating and antineoplastic activities. The TILs are isolated from an autologous tumor sample and transduced with a lentiviral vector to express IL-7. Upon infusion of the autologous IL-7-expressing TILs ADP-TILIL7 back into the patient, the TILs specifically recognize, target and kill the patient's tumor cells. IL-7 is a cytokine that promotes the proliferation and survival of T cells and may enhance the activity and durability of the TILs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous engineered TILs ADP-TILIL7
autologous IL-7-transduced TILs ADP-TILIL7
autologous TILs expressing IL-7 ADP-TILIL7
Code name:ADP TILIL7
ADP-TILIL7
ADPTILIL7
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search